Table 3 Percentage of leukocyte populations and cell ratios in patients with nAMD with and without subretinal fibrosis.
From: Alterations in Circulating Immune Cells in Neovascular Age-Related Macular Degeneration
Variables | Controls (mean ± SD) n= 26 | Fibrosis absent (mean ± SD) n= 66 | Fibrosis present (mean ± SD) n= 37 | Univariate analysis | Multivariate analysis (age and gender) | ||
---|---|---|---|---|---|---|---|
P value fibrosis absent vs present 1 | P value fibrosis absent vs present 2 | Odds ratio | 95% confidence interval for odds ratio | ||||
Cell subsets (FSC/SSC plot) | |||||||
Lymphocytes (%) | 30.45 ± 7.82 | 26.17 ± 7.4 | 27.11 ± 6.19 | 0.517 | |||
Monocytes (%) | 7.28 ± 1.88 | 8.09 ± 2.71 | 7.43 ± 2.32 | 0.215 | |||
Neutrophils (%) | 59.80 ± 8.73 | 63.80 ± 8.25 | 63.55 ± 6.37 | 0.869 | |||
Neutrophil/Lymphocyte ratio | 2.16 ± 0.84 | 2.75 ± 1.22 | 2.51 ± 0.77 | 0.515 | |||
Cell subsets (CD antigens) | |||||||
CD14+ (%) | 7.35 ± 1.95 | 7.75 ± 2.39 | 7.35 ± 1.96 | 0.447 | |||
CD4+ (%) | 12.21 ± 3.92 | 10.82 ± 4.08 | 12.44 ± 4.37 | 0.042 | 0.026 | 37.08 | 1.53–899.43 |
CD8+ (%) | 5.86 ± 2.96 | 5.39 ± 3.8 | 4.51 ± 2.85 | 0.326 | |||
CD19+ (%) | 3.41 ± 2.16 | 2.95 ± 1.69 | 2.53 ± 1.07 | 0.249 | |||
CD56+ (%) | 3.27 ± 1.66 | 3.49 ± 1.57 | 3.42 ± 2.34 | 0.340 | |||
CD11b+ (%) | 67.40 ± 9.00 | 72.97 ± 8.47 | 72.48 ± 6.55 | 0.797 | |||
CD16hiHLA-DR− Neutrophils (%) | 57.80 ± 9.05 | 63.33 ± 8.7 | 62.95 ± 6.21 | 0.798 | |||
CD16hiHLA-DR−/(CD4 + CD8) ratio | 3.51 ± 1.49 | 4.60 ± 2.06 | 4.13 ± 1.56 | 0.462 | |||
CD16hiHLA-DR−/CD4 ratio | 5.34 ± 2.34 | 6.80 ± 3.07 | 5.65 ± 1.97 | 0.120 | |||
CD16hiHLA-DR−/CD8 ratio | 13.80 ± 11.28 | 19.10 ± 15.52 | 21.02 ± 17.48 | 0.381 | |||
CD16hiHLA-DR−/CD19 ratio | 25.69 ± 21.26 | 31.16 ± 27.45 | 33.55 ± 26.44 | 0.354 | |||
CD16hiHLA-DR−/CD56 ratio | 22.41 ± 11.25 | 22.91 ± 15.72 | 29.25 ± 23.86 | 0.274 |